(thirdQuint)Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers.

 OBJECTIVES: - Determine the efficacy and feasibility of celecoxib for chemoprevention of primary non-small cell lung cancer in high-risk tobacco smokers.

 - Determine the safety and long-term side effects of this drug in this population.

 OUTLINE: Patients receive oral celecoxib twice daily for 6 months.

 Patients are followed at 2 weeks and then at 6 months.

 PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 6 months.

.

 Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers@highlight

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer.

 Celecoxib may be effective in preventing lung cancer in tobacco smokers.

 PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.

